RT Book, Section
A1 Krasna, Mark J.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105839054
T1 Left Transthoracic Esophagectomy (Ellis)
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105839054
RD 2024/04/24
AB The  worldwide  estimate  for  new  cases  of  esophageal  cancer  was  482,300  in  2008.1  In  2012  over  17,500  new  cases  of  esophageal  cancer  were  diagnosed  in  the  United  States  alone,  with  over  15,000  deaths.  Despite  advances  in  chemotherapeutic  agents  and  radiation  therapy,  surgery  remains  the  core  component  of  treatment  of  this  disease.  Especially  in  early-stage  disease,  surgery  is  still  offered  as  definitive  therapy.  The  incidence  of  esophageal  adenocarcinoma  has  been  increasing  steadily  in  the  United  States.2,3  Adenocarcinoma  of  the  esophagus  develops  predominantly  in  a  segment  of  intestinal  metaplasia,  and  thus  the  increased  incidence  of  esophageal  adenocarcinoma  translates  into  an  increasingly  prevalent  disease  in  the  distal  third  of  the  esophagus.4  Given  the  anatomic  configuration  of  the  esophagus  within  the  thoracic  cavity,  no  one  surgical  incision  provides  uniform  access  to  the  entire  esophagus.  The  surgical  approach  therefore  must  be  tailored  to  the  individual  patient,  permitting  adequate  exposure  to  the  diseased  region  of  the  esophagus  with  the  least  amount  of  invasiveness.